Puma Biotechnology, Inc. (PBYI)
| Market Cap | 467.68M +82.0% |
| Revenue (ttm) | 231.24M -2.9% |
| Net Income | 26.72M -44.9% |
| EPS | 0.50 -48.2% |
| Shares Out | 51.62M |
| PE Ratio | 17.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 235,034 |
| Open | 9.24 |
| Previous Close | 9.24 |
| Day's Range | 9.02 - 9.26 |
| 52-Week Range | 4.30 - 9.51 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]
Financial Performance
In 2025, Puma Biotechnology's revenue was $228.37 million, a decrease of -0.91% compared to the previous year's $230.47 million. Earnings were $31.11 million, an increase of 2.75%.
Financial StatementsNews
Puma Biotechnology price target raised to $6 from $5 at TD Cowen
TD Cowen analyst Marc Frahm raised the firm’s price target on Puma Biotechnology (PBYI) to $6 from $5 and keeps a Hold rating on the shares. The firm updated its…
Puma Biotechnology reports Q2 EPS 19c vs 15c last year
Reports Q2 revenue $56.5M vs $52.4M last year. “We are pleased with our commercial execution in the second quarter and the continued increase in year-over-year demand for NERLYNX. We are…
Puma Biotechnology sees Q3 revenue $56M-$59M
Sees Q3 royalty revenue $2M-$3M, net product revenue $54M-$56M
Puma Biotechnology raises FY26 revenue to $224M-$231M from $222M-$229M
Sees FY26 net produce revenue $202M-$206M, sees FY26 royalty revenue $20M-$23M
Puma Biotechnology Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue and net income growth, driven by increased NERLYNX demand and disciplined expense management. Guidance for FY 2026 was raised for both product revenue and net income, while the company remains debt-free and continues to advance its clinical pipeline.
Puma Biotechnology Earnings release: Q2 2026
Puma Biotechnology released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Puma Biotechnology Quarterly report: Q2 2026
Puma Biotechnology has published its Q2 2026 quarterly earnings report on August 6, 2026.
Puma Biotechnology Slides: Q2 2026
Puma Biotechnology has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Puma Biotechnology Reports Second Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its inducement awards granted for July 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on August 6, 2026, following release of its 2Q-2026 results.
Puma Biotechnology reports Q1 adjusted EPS (4c) vs (10c) last year
Reports Q1 revenue $44.8M vs $42M last year. “We are very pleased that the first quarter of 2026 marked another quarter of year-over-year demand increase resulting in our raising revenue…
Puma Biotechnology sees Q2 revenue $52M-$55M, one estimate $52M
16:58 EDT Puma Biotechnology (PBYI) sees Q2 revenue $52M-$55M, one estimate $52M
Puma Biotechnology raises FY26 revenue view to $222M-$229M from $214M-$221M
One estimate $218M.
Puma Biotechnology Earnings Call Transcript: Q1 2026
Q1 2026 saw NERLYNX revenue decline sequentially due to inventory drawdown, but new patient starts rose 25% and the company is now debt-free. Updated guidance raises FY 2026 revenue and net income expectations, with strong clinical progress in biomarker-driven trials.
Puma Biotechnology Earnings release: Q1 2026
Puma Biotechnology released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Puma Biotechnology Quarterly report: Q1 2026
Puma Biotechnology has published its Q1 2026 quarterly earnings report on May 7, 2026.
Puma Biotechnology Slides: Q1 2026
Puma Biotechnology has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Puma Biotechnology Reports First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 financial results.
Puma Biotechnology Proxy statement: Proxy filing
Puma Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Puma Biotechnology Proxy statement: Proxy filing
Puma Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.
Puma Biotechnology Proxy statement: Proxy filing
Puma Biotechnology filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Puma Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
NERLYNX continues to show strong commercial growth, with increasing revenues and improved patient tolerability. Alisertib advances in phase II trials for breast and lung cancers, with interim and full data readouts expected in 2026. Financial stability is supported by profitability and a near debt-free position.
Puma Biotechnology reports Q4 EPS 26c vs. 39c last year
Reports Q4 revenue $75.5M vs. $59.1M last year. “Our financial performance in the fourth quarter and full year 2025 demonstrates continued momentum, with net income marking our third consecutive year…